Advertisement

Search Results

Advertisement



Your search for them matches 6128 pages

Showing 4351 - 4400


Junior Investigators Win Awards for Pilot Projects

The results of the Fox Chase Cancer Center’s American Cancer Society Institutional Research Grant (IRG) Pilot Project Competition for Junior Investigators that was held in December 2015 have been announced. The competition was open to eligible junior faculty at Fox Chase Cancer Center or Temple...

Mary-Claire King, PhD, Awarded 2016 Szent-Györgyi Prize for Progress in Cancer Research

The National Foundation for Cancer Research has announced that Mary-Claire King, PhD, Professor of Genome Sciences and Medicine (Medical Genetics) at the University of Washington, Seattle, has been awarded the 2016 Szent-Györgyi Prize for Progress in Cancer ­Research. The National Foundation for...

breast cancer

Men Get Breast Cancer Too

Like many men, it never occurred to me that I could get breast cancer. But it turns out it is more common—and deadly—than I thought, with about 2,600 men diagnosed each year with invasive breast cancer and nearly 440 dying of the disease.1 In 2010, I became one of those men, and the diagnosis was...

Expect Questions About Updated Dietary Guidelines

The 2015–2020 Dietary Guidelines for Americans1 have generated comments and controversy, with some organizations expressing concern that the guidelines did not recommend limiting the consumption of red and processed meat. These organizations include the American Institute for Cancer Research...

issues in oncology

Failure of Updated Dietary Guidelines to Advise Limiting Red and Processed Meat Deemed a ‘Missed Opportunity’

“A missed opportunity” is how Susan Higginbotham, PhD, RD, Vice President for Research, American Institute for Cancer Research (AICR), described the “failure” of updated dietary guidelines to recommend limiting consumption of red and processed meat. Doing so would have “the potential to save...

supportive care

Rolapitant Reduces Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately and Highly Emetogenic Chemotherapy

In three phase III studies reported in The Lancet Oncology, the addition of the neurokinin-1 (NK-1) receptor antagonist rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in the prevention of chemotherapy-induced nausea and ...

health-care policy
issues in oncology

Evolving Tools for Clinical Decision-Making

Value in cancer care—and how to define it—is a hot topic. There is general agreement that it is some measure of benefit vs cost, but “should the focus be on providing value to patients at a population level or at an individual level?” asked Alan Balch, PhD, CEO of the Patient Advocate Foundation,...

prostate cancer

Active Holistic Surveillance May Prevent Unnecessary Biopsies in Low- and Low/Intermediate-Risk Prostate Cancer

The use of prostate-specific antigen (PSA) screening has led to a dramatic rise in the number of men diagnosed with low-grade prostate cancer. Active surveillance is recommended to manage patients with favorable-risk, low-grade prostate cancer, with the goal of avoiding overtreatment of these...

prostate cancer

New Technology to Characterize Circulating Tumor Cells Suggests Better Treatment Decision-Making in Prostate Cancer

An early study showed that an experimental blood test (ie, “liquid biopsy”) that characterizes the phenotype and genomic characteristics of circulating tumor cells appears to have utility in personalizing treatment decisions for individual men with advanced prostate cancer.1 The assay—developed and ...

Expert Point of View: Kathryn Schmitz, PhD, MPH

Discussant Kathryn Schmitz, PhD, MPH, Professor of Epidemiology at the Perelman School of Medicine, University of Pennsylvania, lauded the researchers’ successful intervention in what can be a challenging setting. “Dr. Yung presented evidence that it is feasible to conduct an evidence-based,...

survivorship

Bridging the Medical Gap in Long-Term Cancer Survivorship Care

Although more people than ever before are surviving cancer—there are currently 14.5 million cancer survivors, and that number is expected to climb to 19 million by 20241—they often experience long-lasting physical, emotional, and financial concerns related to the disease. To address the unmet...

cost of care

Cost in the Context of Value for Cancer Medicines

Bringing new cancer therapies through the discovery and development process entails considerable risk and many years of study. It also requires substantial investment and incentives from the public and private sectors to fuel future investment and discovery. A system that rewards advances in cancer ...

gastrointestinal cancer

Anti–PD-1/PD-L1 Antibodies Make Strong Showing in Gastrointestinal Cancers

Although the results may not yet be as impressive as those seen in melanoma, lung, and kidney cancers, monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) are producing responses, with some durability, in gastrointestinal cancers, according to studies presented at the 2016...

sarcoma

Eribulin Improves Overall Survival vs Dacarbazine in Advanced Liposarcoma or Leiomyosarcoma

In a phase III trial reported in The Lancet, Schöffski et al found that eribulin improved overall survival vs dacarbazine in patients with advanced or metastatic soft-tissue sarcoma who had received at least two prior systemic treatments for advanced disease. Outcome in the subgroup with...

leukemia
lymphoma

Younger T Cells May Improve Immunotherapy for Pediatric Cancer

Pediatric oncologists from The Children’s Hospital of Philadelphia (CHOP) have investigated techniques to improve and broaden a novel personalized cell therapy to treat children with cancer. The researchers say that a patient’s outcome may be improved if clinicians select specific...

Study Examines Evolution of Cancer

A novel Yale University study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead to more effective targets for treatment, said the researchers. The...

issues in oncology

Interruption of Radiation Therapy Due to Noncompliance Risks Cancer Recurrence

Cancer patients who miss two or more radiation therapy sessions (except for planned treatment breaks) have a worse outcome than fully compliant patients, investigators at Montefiore Einstein Center for Cancer Care (MECCC) and Albert Einstein College of Medicine's Albert Einstein Cancer Center have...

pancreatic cancer
issues in oncology

Preclinical Device Hits Pancreatic Tumors With Drug Cocktail, Sparing the Body

A highly lethal cancer sometimes requires large doses of highly toxic drugs. However, a blitzkrieg approach can be unfeasible for some patients due to severe side effects. Now a team of researchers at the University of North Carolina at Chapel Hill has found that an implantable device can deliver a ...

leukemia
lymphoma
survivorship

Reduction in Late Mortality in Childhood Cancer Survivors in the Childhood Cancer Survivor Study Cohort

In a study reported in The New England Journal of Medicine, Armstrong et al found that late mortality decreased over time among 5-year survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. The reduction is consistent with efforts during recent decades to modify treatment with ...

Immunotherapy Expert Crystal Mackall, MD, Joins Stanford Medicine Faculty

Cancer immunotherapy expert Crystal Mackall, MD, joined the Stanford University School of Medicine faculty on January 1 as Professor of Pediatrics and Medicine, as well as Associate Director of the Stanford Cancer Institute and Co-Medical Director of the Stanford Laboratory for Cell and Gene...

Certainty

The following essay by William N. Harwin, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org.   My wife...

Misconstrued Review

I’ve been a member of ASCO for longer than I can remember. I read most breast cancer–related articles in The ASCO Post and find them helpful, particularly the reports of as-yet-unpublished papers from meetings. So, it is with great disappointment that, in the November 10, 2015, issue, I read a...

A Pioneering Oncologist’s Roadmap Forward

Bookmark Title: The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable—and How We Can Get There Authors: Vincent T. DeVita, Jr, MD, and Elizabeth DeVita-Raeburn Publisher: Farrar, Straus and Giroux Publication date:...

breast cancer

Looking at the Real-World Effects of Genetic Testing

According to the most recent estimates, 55% to 65% of women who inherit the BRCA1 mutation and about 45% of women who inherit the BRCA2 mutation will develop breast cancer by the time they are 70 years old. There is also a substantial increase in the probability of developing ovarian cancers in...

Defibrotide Under Review for Transplant-Related Complication

A potentially fatal complication of hematopoietic stem cell transplantation may be reversed with the use of a novel drug currently under priority review at the U.S. Food and Drug Administration (FDA). Hepatic veno-occlusive disease/sinusoidal obstruction syndrome is usually a serious complication...

Expert Point of View: C. Kent Osborne, MD

These data will help us personalize treatment for our patients. We still don’t know which women with a favorable cancer like ductal carcinoma in situ are most likely to progress. This is an unmet need,” said C. Kent Osborne, MD, Director of the Dan L. Duncan Cancer Center at Baylor College of...

breast cancer

Tamoxifen or Anastrozole for Ductal Carcinoma in Situ?

Ductal carcinoma in situ is a relatively benign form of breast cancer (stage 0), yet up to 10% of women with ductal carcinoma in situ will have a recurrence within 10 years. At present, there is no way to identify which women will recur, so standard treatment is lumpectomy plus radiation therapy....

breast cancer

Synthetic 2D Mammography May Hold Advantages Over 2D/3D Mammography

In screening for breast cancer, results from a study in the United Kingdom suggest that the use of “synthetic” two-dimensional (2D) mammography, rather than 2D/three-dimensional (3D) combinations, could save radiologists’ time and patients’ exposure to radiation as well as result in many fewer...

breast cancer

Selected Abstracts From 2015 San Antonio Breast Cancer Symposium

The 2015 San Antonio Breast Cancer Symposium (SABCS), hosted by the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine, was held in December 2015. As has been true for...

issues in oncology

Cancer Registries and the Evolving Role of Big Data in Cancer Care

In 1956, the American College of Surgeons encouraged the development of hospital-based registries, but for the most part, these efforts were clumsy, inaccessible card files of data. Today, advanced microcomputer technology has increased the ability to not only collect and cull cancer data but also...

issues in oncology

'Doctor, We Prayed for You'

A 70-year-old female patient underwent a cardiac procedure to repair her mitral valve, and at the same time, she also underwent a coronary artery bypass grafting. She had an uneventful course for the first four postoperative days. On the sixth postoperative day, she started complaining of abdominal ...

gynecologic cancers
issues in oncology

Sparing Ovaries and Removing Fallopian Tubes May Cut Cancer Risk, but Few Have Procedure

During hysterectomies for noncancerous conditions, removing both fallopian tubes while keeping the ovaries may help protect against ovarian cancer and preserve hormonal levels, but few women receive this surgical option, according to a new study by Yale School of Medicine researchers. Published by ...

cns cancers
issues in oncology

Abnormal Fused Gene Is a Triple Threat in Driving Pediatric Brain Tumors

Oncology researchers have discovered that an abnormal fused gene that drives pediatric brain tumors poses a triple threat, operating simultaneously through three distinct biologic mechanisms—the first such example in cancer biology. The study was published by Bandopadhayay et al in Nature...

breast cancer
issues in oncology

Higher Dietary Fiber Intake in Adolescence and Young Adulthood May Reduce Breast Cancer Risk

Women who eat more high-fiber foods during adolescence and young adulthood—especially fruits and vegetables—may have significantly lower breast cancer risk than those who eat less dietary fiber when young, according to a new large-scale study led by researchers at Harvard T.H. Chan...

UK Study Finds No Association Between Self-Reported Unhappiness and Mortality Risk

As reported in The Lancet by Liu et al, a study in UK women that attempted to adjust for the effect of health and lifestyle factors found that self-reported unhappiness was not associated with an increased risk of mortality from cancer or other conditions. Study Details The study involved data...

Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO, on 20 Years of Improving Cancer Care Together: A Clinical Perspective

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Al B. Benson III, MD, FACP, FASCO, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of NCCN Guidelines, which are available free online,  and the components that ...

supportive care
survivorship

Julia H. Rowland, PhD, on The Psychosocial Challenges Cancer Survivors Face

Julia H. Rowland, PhD, of the National Cancer Institute, discusses the growing number of promising interventions to improve health and function for those living with and beyond a cancer diagnosis, as well as those who care for and about them.

survivorship

Christopher J. Recklitis, PhD, MPH, on Fatigue and Sleep Disturbances

Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute, discusses these side effects and some practical approaches to managing them with educational, medical, behavioral, and lifestyle interventions.

Famed Cancer Biostatistician, Norman Breslow, PhD, Dies

A longitudinal case-controlled analysis of the probability of attaining normality after achieving 60: A perspective from the social sciences based on expert ethnographic insights.” So begins a long and charmingly erudite birthday card to internationally regarded biostatistician Norman Breslow, PhD, ...

Nationally Regarded Cancer Advocate Ellen Stovall Dies

Passion is a much-needed virtue in one who seeks to change the world for the better. When you combine intelligence, stamina, iron-willed determination, the grace of an ambassador, and simple human likability with passion, you get that rare person who can turn words and ideas into reality. Such a...

issues in oncology

Pieces of Grief

The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...

Saving Children Orphaned by AIDS in South Africa

Bookmark Title: Empty Hands, A Memoir: One Woman’s Journey to Save Children Orphaned by AIDS in South Africa Author:  Sister Abegail Ntleko Publisher: North Atlantic Books Publication date: September 1, 2015 Price: $12.95; paperback, 176 pages With the development of the multidrug highly active...

breast cancer
issues in oncology

The New Frontiers of Breast Cancer

A seismic shift is underway in screening and treatment approaches for breast cancer. These changes are being fueled by studies showing that mammography in younger women may do more harm than good and that advances in genomic testing and a better understanding of the biology of breast cancers may...

issues in oncology

E-Cigarette Advertisements Reach Nearly 7 in 10 Middle and High School Students

About 7 in 10 middle and high school students—more than 18 million young people—see e-cigarette advertising in stores, online, in newspapers and magazines, or on television and in movies, according to a new Centers for Disease Control and Prevention (CDC) Vital Signs report. E-cigarette ads use...

palliative care

How Effective Communication Can Improve Patient Care—and Reduce Physician Burnout

Surveys conducted between 1950 and 1970 show that most physicians considered it inhumane to give patients with a poor cancer prognosis the bad news.1,2 Since then, it has been well established that open communication between physician and patient is an essential part of effective cancer care and...

Raymond N. DuBois, MD, PhD, Named Dean of the MUSC College of Medicine

The Medical University of South Carolina (MUSC) has named Raymond N. DuBois, MD, PhD, as the next Dean of the College of Medicine. Dr. DuBois will assume his new role effective March 1, 2016, with an academic appointment as Professor in the College of Medicine while also holding an appointment in...

Expert Point of View: George Daley, MD, PhD, and David Williams, MD

Press briefing moderator George Daley, MD, PhD, of Boston Children’s Hospital, was enthusiastic about these results, despite the small number of patients treated in studies of CAR-T cells thus far. Most of the results have been in a positive direction, he noted. “It is remarkably exciting to see...

hematologic malignancies

New Use for CAR-T Cells Post Transplantation

The approach of using genetically engineered chimeric antigen receptor (CAR)-T cells has received much attention for treating leukemias, where it has achieved spectacular long-lasting complete remissions in some patients with no other treatment options. CAR-T cells are also being studied in...

leukemia

Severe Toxicities Seen in Younger Patients Receiving  Front-Line Idelalisib for Chronic Lymphocytic Leukemia

Hematologists and patients with chronic lymphocytic leukemia (CLL) are excited about new drugs that have dramatically improved outcomes. But all drugs have side effects, and it is important to be aware of potential consequences. Hepatotoxicity turns out to be a major concern in younger CLL patients ...

Expert Point of View: Daniel Hayes, MD

In an interview with The ASCO Post, 2016 President-Elect of ASCO Daniel Hayes, MD, explained his interest in what he labeled “very exciting technology.” “Most of the DNA in plasma is normal, coming from white cells. Within that, there’s a small amount of tumor DNA. I have been told that you either...

Advertisement

Advertisement




Advertisement